Aptose Biosciences Inc (APTO)

[dcaf7]

Nothing to compare. As you know, easiest and fastest way to bring Tusp to the market is accelerated approval for use in patients progressed on Flt3 inhibitors. Aptose already demonstrated that Tusp is active in some patients after Gilteritinib or Midostaurine treatment. But we don't know whether Tusp is active after Quizartinib or not. Quiz works by a different mechanism as compared to Gilt and it can inhibit other TKs, like Tusp. Keep in mind that Quiz is now approved in 1st line. Expect many patients pre-treated with Quiz before they are eligible for Tusp.